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Abstract  
Lonidamine (LND) was initially introduced as an antispermatogenic agent. It was later found 
to have anticancer activity sensitizing tumors to chemo-, radio-, photodynamic-therapy and 
hyperthermia. Although the mechanism of action remained unclear, LND treatment has been 
known to target metabolic pathways in cancer cells. It has been reported to alter the 
bioenergetics of tumor cells by inhibiting glycolysis and mitochondrial respiration, while 
indirect evidence suggested that it also inhibited L-lactic acid efflux from cells mediated by 
members of the proton-linked monocarboxylate transporter (MCT) family and also pyruvate 
uptake into the mitochondria by the mitochondrial pyruvate carrier (MPC). Recent studies have 
demonstrated that LND potently inhibits MPC activity in isolated rat liver mitochondria (Ki 2.5 
μM) and cooperatively inhibits L-lactate transport by MCT1, MCT2 and MCT4 expressed in 
Xenopus laevis oocytes with K0.5 and Hill Coefficient values of 36-40 μM and 1.65-1.85, 
respectively. In rat heart mitochondria LND inhibited the MPC with similar potency and 
uncoupled oxidation of pyruvate was inhibited more effectively (IC50 ~7 μM) than other 
substrates including glutamate (IC50 ~20 μM). LND inhibits the succinate-ubiquinone 
reductase activity of respiratory Complex II without fully blocking succinate dehydrogenase 
activity. LND also induces cellular reactive oxygen species through Complex II and has been 
reported to promote cell death by suppression of the pentose phosphate pathway, which 
resulted in inhibition of NADPH and glutathione generation. We conclude that MPC inhibition 
is the most sensitive anti-tumour target for LND, with additional inhibitory effects on MCT-
mediated L-lactic acid efflux, Complex II and glutamine/glutamate oxidation. 
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Introduction 
Lonidamine (LND), first introduced in 1979 as an antispermatogenic agent (1), has limited 
antineoplastic activity as a single agent but has exceptional potential in modulating the 
activities of conventional chemotherapeutic agents such as platinum alkylating agents, (2) N-
mustards (3-7) and anthracyclines (8) as well as hyperthermia (9-11), radiation therapy (12, 13) 
and  photodynamic therapy (14); it may also enhance tumor uptake of targeted therapeutics. 
The most critical property of LND is its selective activity against a broad range of tumors with 
little to no effect on normal tissues provided that doses are below a threshold level of ~400 
mg/m
2
 (oral or i.v. doses) (15, 16). At such doses LND causes selective intracellular cytosolic 
acidification of tumors while diminishing tumor ATP levels. 
Current evidence indicates that LND inhibits lactate export by the proton-linked 
monocarboxylate transporter(s) (MCT) and pyruvate uptake into mitochondria via the 
mitochondrial pyruvate carrier (MPC), whereas inhibition of respiration involves both 
diminished mitochondrial uptake of pyruvate via the MPC as well as inhibition of the 
mitochondrial electron-transport chain at Complex II and perhaps also Complex I, in both 
instances at the ubiquinone reduction step. There is also evidence that the drug may indirectly 
inhibit hexokinase (17-20) as well as possibly at other glycolytic and pentose shunt enzymes as 
a result of cytosolic acidification. LND produces a substantial increase in total tumor lactic 
acid levels with most of the lactate being trapped in the cytosol as indicated by pronounced 
decreases in intracellular pH (pHi); there is also a slight decrease in extracellular pH (pHe) 
reflecting a small extent of leakage of lactate through the MCT (6-8). However, direct evidence 
for LND inhibition of the MPC, any of the four MCT isoforms known to transport lactic acid 
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(21) as well as inhibition of mitochondrial electron-transport has until recently been lacking. In 
this review article, we present data addressing these issues.  
Contemporary Background 
In 1981, Floridi et al. (22) reported that LND inhibited respiration as well as aerobic and 
anaerobic glycolysis in Ehrlich ascites tumor cells but had no effect on normal rat sertoli cells. 
They attributed the selective inhibition of glycolysis in tumor cells to LND binding to and 
inhibiting mitochondrial bound hexokinase that Mathupala et al. (23) have shown existed 
mainly in tumor cells. In 1982, Floridi et al. (24) demonstrated that LND affected respiration of 
Ehrlich ascites cells only in the uncoupled state but not in the coupled state. Scatchard analysis 
indicated two classes of binding sites in uncoupled mitochondria, a high affinity site with 
dissociation constants (Kd) of 3.2 µM and a weaker but more highly populated site with Kd of 
45 µM. Binding of LND to normal liver mitochondria was qualitatively similar but with lower 
affinity than binding to tumor mitochondria. Further studies of LND inhibition of the 
mitochondrial electron transport chain of Ehrlich ascites cells were reported by Floridi and 
Lehninger in 1983 (25). They concluded that LND was bound to mitochondria in state 4 but 
did not inhibit respiration in this state except at concentrations above 200 M. Half-maximal 
inhibition of respiration of FCCP (carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone)-
stimulated tumor mitochondria occurred at 32 M LND with almost complete inhibition of 
LND concentrations greater than 200 M. They concluded that LND shifted mitochondrial 
NAD(P) into a more oxidized steady state. Subsequent addition of an uncoupler or ADP, which 
would normally induce respiration, increases LND binding and inhibition of reduction of 
NAD(P) by mitochondrial dehydrogenases. The precise mechanism of interaction with the 
mitochondrial electron transport chain was not clearly defined although the authors noted that 
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LND appears to affect the state 4 to state 3 transitions. It is noteworthy that the authors 
recognized that LND inhibits the reduction of NAD(P) by various NAD-linked substrates 
(pyruvate + malate, α-ketoglutarate and glutamate) and that it inhibits succinate dehydrogenase 
at some point prior to the reduction to ubiquinone.  
 In 1995 Ben-Horin et al. (26) reported 
31
P and 
13
C NMR (nuclear magnetic resonance) 
spectroscopic studies of isolated perfused MCF7 breast cancer cells immobilized by 
encasement in calcium alginate beads. By incorporating Pi (inorganic phosphate) into the 
perfusate, the authors were able to detect two Pi resonances, which they used to simultaneously 
monitor both the pHi and pHe, respectively. LND produced a decrease in pHi with no effect on 
pHe. Furthermore, 
13
C NMR demonstrated that this decrease in pHi was accompanied by 
accumulation of lactic acid in the intracellular compartment, and depletion of extracellular 
lactate. The evidence clearly pointed to inhibition of lactate export (i.e., via MCTs) as a key 
mechanism responsible for LND-induced tumor acidification. Rather than inhibiting 
glycolysis, the accumulation of intracellular lactate indicated that LND was stimulating 
glycolysis, although kinetic inhibition of certain steps along the glycolytic pathway might still 
be occurring since it is well known that enzymes such as phosphofructokinase are subject to 
allosteric H
+
 inhibition. These investigators also noted that LND decreased NTP (nucleoside 
triphosphate) levels in the tumor, which also decreased phospholipid metabolites as a 
consequence of diminution of choline and ethanolamine kinase activities. The decrease in the 
bioenergetic status of the tumors was attributed to the effect of LND on mitochondrial 
metabolism that had been reported by Floridi et al. (25). 
Mardor et al. (27) combined NMR studies of MCF7 cells with diffusion-weighted 
imaging of perfused cells, a method that eliminates signals from metabolites in the perfusate.  
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This ability to distinguish between intracellular and extracellular compartments further 
supported the conclusions of Ben-Horin et al. (26). 
These NMR studies of breast cancer cells were confirmed and extended by studies of 
9L glioma cells and 9L glioma xenografts by Ben-Yoseph et al. (28). Using 
31
P NMR, these 
investigators demonstrated that LND produced intracellular acidification and de-energization 
both in culture and in vivo and showed that the in vivo effects were selective for the tumor with 
no effect on skeletal muscle or brain.  
Selective Intracellular Acidification and De-energization of Various Human Cancer 
Xenografts 
In 2000 (29) and 2001 (30), Zhou et al. demonstrated by 
31
P NMR studies of DB-1 melanoma 
xenografts that LND had a similar but more pronounced and sustained effect on tumor pHi and 
NTP levels than α-cyano-4’-hydroxycinnamate (CHC), an agent that Halestrap et al. (21, 31) 
had demonstrated to be a potent inhibitor of the MCT and the MPC. Zhou et al. (30) showed 
that the effects of CHC were specific for the tumor with no effect on the metabolism of skeletal 
muscle, liver or brain.  
 In 2013, Nath et al. (7) reported that administration of 100 mg/kg LND i.p as a solution 
in pH 8.3 tris-glycine buffer (the method used by Ben-Yoseph et al. (24)) monitored by 
31
P 
NMR spectroscopy that LND produced a sustained intracellular acidification of DB-1 
melanoma xenografts with pHi decreasing from 6.90  ± 0.05 to 6.33 ± 0.10 (p < 0.001) for 3 hr 
post-injection (Figure 1 and Table 1). DB-1 tumors have a relatively high rate of glycolysis as 
defined by a significant rate of lactic acid production. As such, it is possible that MCT 
transport of lactate becomes limiting. This in concert with a slow clearance of extracellular 
lactate might provide a rationale for the slightly acidic basal pHi observed in the DB-1 
8 
 
melanoma tumor model. The acidification was accompanied by a decrease in NTP levels and 
an increase in Pi levels that was sustained over the same period of time as the intracellular 
acidification of the tumor. The βNTP/Pi ratio, that reflects the bioenergetic state of the tumor, 
decreased by 66.8 ± 5.7% (p < 0.001) 3 hr post-LND injection (Figure 1 and Table 1). The 
pHe of the tumor decreased slightly from 7.00 ± 0.04 to 6.80 ± 0.07, p > 0.05 (Figure 1 and 
Table 1). CHC had produced similar effects, but the acidification and de-energization of the 
tumor was of substantially shorter duration. 
1
H MRS (magnetic resonance spectroscopy) of 
lactate demonstrated a 3-fold increase in lactic acid levels in the tumor after LND treatment 
providing further evidence that glycolytic metabolism was not inhibited although kinetic 
effects were not excluded (Figure 1 and Table 1). Nath et al. (7) demonstrated that 
acidification and de-energization were selective for the tumor with no change in pHi, pHe or 
NTP/Pi of skeletal muscle or brain and only a slight transient decrease in pHi of liver 20 min 
post-LND injection and a decrease in NTP/Pi of liver 40 min post-LND. Ben-Yoseph et al. 
(28) also demonstrated selective acidification and de-energization of gliomas in rats with no 
significant effects on muscle or brain. Selectivity for tumors probably results from their higher 
glycolytic capacity although perfused DB-1 melanoma cells derive 54% of their energy from 
oxidative metabolism and 46% by glycolysis as shown by Shestov et al. (32).  
In 2015 Nath et al (8) demonstrated by 
31
P NMR that 100 mg/kg LND has similar 
effects on two breast carcinoma lines--the triple negative HCC1806 subline that lacks estrogen, 
progesterone and Her2/Neu receptors and the BT-474 line that expresses each of these 
receptors-and also in human prostate (LNCaP) and on ovarian carcinoma xenografts (A2780). 
Each of these tumors exhibited a rapid decrease in pHi, a small decrease in pHe, and a 
concomitant monotonic decrease in bioenergetics (βNTP/Pi) over a 2-3 h period (Table 1). 
9 
 
Potentiation of Chemotherapeutic Efficacy of Nitrogen Mustard and Doxorubicin 
Nath et al. (7) also demonstrated that LND potentiated the activity of melphalan (7.5 mg/kg; 
i.v.) (Figure 2 and Table 2) in DB-1 melanoma xenografts and also enhanced the activity of 
doxorubicin in DB-1 melanoma (7.5 mg/kg and 10 mg/kg; i.v.) and in HCC1806 (12 mg/kg; 
i.v.) breast cancer xenografts (Table 2). Panel D in figure 1 demonstrated that it takes greater 
than 40 min to maximize effects on pHi after administration of LND (100 mg/kg; i.p.). 
Chemotherapeutic agent such as nitrogen mustards, doxorubicin, were administered by i.v. 
injection 40 min post injection of LND in order to achieve maximum effect  In the case of N-
mustards (6, 7, 33), LND-induced potentiation of chemotherapeutic activity most likely due to 
three known effects: 1) increased concentrations of the active intermediate cyclic aziridinium 
ion intermediate, 2) decreased concentrations of competing nucleophiles such as hydroxide and 
glutathione, whose production is diminished by decreased activity of gluthathione-S-
transferase under acidic conditions, and 3) decreased DNA repair due to acid inhibition of O
6
-
alkyltransferase (34-36). The enhancement of tumor response to doxorubicin probably resulted 
from cation-trapping of the weakly basic anthracycline in the tumor (8). The pHi was more 
acidic than the pHe (reversing the translammelar pH gradient generally observed in tumors 
(37-39), and a weak base was, therefore, accumulating by a cation-trapping mechanism – i.e., 
the neutral free base was entering the cell by diffusion, becoming protonated once it entered 
the cell and, thereby, being trapped in the cell because it became positively charged and could 
not diffuse out. However, the LND-induced decrease in tumor NTP levels may also contribute 
to the enhanced activity of doxorubicin by decreasing multi-drug resistance of the tumor to 
anthracyclines, an energy dependent process that pumps drugs out of the tumor cell (40).  
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Hyperglycemia Induced Selective Intracellular Acidification and De-energization and 
Sensitization to Melphalan 
Nath et al (6) later undertook studies to determine whether the addition of exogenous glucose 
to mice implanted with DB-1 melanoma can further increase LND-induced tumor acidification 
by increasing lactate production and whether hyperglycemia can increase the tumor response to 
melphalan. Comparative data on normal liver, skeletal muscle and brain was obtained to 
determine whether LND has a selective effect on tumors and to delineate possible mechanisms 
underlying this selectivity (6). These studies pointed to the potential utility of nitrogen 
mustards and LND in the systemic treatment of disseminated melanoma and other 
malignancies. Hyperglycemia resulted in improvement of the bioenergetic state of the tumor 
that diminished the cytotoxic effect of melphalan (6). Since the MCT is the main mechanism 
by which the DB-1 melanoma (7) and most other tumors (8) maintain intracellular pH 
homeostasis, inhibition of this co-transporter could lead to tumor acidification unless the 
excess pyruvate were depleted by mitochondrial oxidation (see below). Delivery of high levels 
of exogenous glucose (26 mM) to the tumor decreased the pHi to 6.17 and increased lactate 
levels ~6 fold. Without exogenous glucose, pHi was 6.33 and lactate had increased ~3 fold 
from baseline following LND administration (7). Tumor cells also maintain pH homeostasis as 
a result of the buffering capacity of CO2. As carbonic acid has a pKa of 6.4, this lack of 
acidification can be attributed to the high buffering capacity of CO2 produced from oxidative 
phosphorylation and/or introduced via the Cl-/HCO3
-
 exchanger. The extent of tumor cell kill 
by melphalan in the presence of glucose diminished (cell kill = 62.8% compared to 89.4% in 
the absence of exogenous glucose). This study indicated that administration of exogenous 
glucose should be avoided in the clinic.  
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The currently available evidence strongly indicates that LND inhibits lactate export by the 
MCT but precisely which isozyme of MCT is being inhibited remains to be determined. The 
mechanism responsible for the selective ability of LND to decrease NTP levels in tumors with 
minimal to no effect on normal tissues remains to be elucidated. The mechanism responsible 
for selective decreases in ATP of tumors compared to normal tissues also requires further 
elucidation. The proposal that LND inhibits mitochondrial electron transport requires 
validation and demonstration of the site of inhibition. These issues have been recently 
addressed and will be summarized in this review. The rationale of the present study was to 
determine whether the extent of tumor acidification could be increased by infusing high 
concentrations of glucose into the mouse to induce an increased rate of glycolysis, resulting in 
higher levels of lactate and increased acidification, and further resulting in greater efficacy of 
response. We believe that our hypothesis was flawed for several reasons: 1) pH balance is 
highly buffered, so even though we greatly increased the production of lactate, infusion of 
glucose failed to decrease pH for this reason, and, 2) For most tissues with adequate perfusion, 
normal physiological levels of glucose (~5 mM) are not limiting to transport of this substrate 
into cells, so that transport of glucose is at Vmax in these cells under basal conditions and not 
influenced by higher levels of glucose. Thus, the increase in lactate production seen in these 
experiments most likely results from those tissues that are limited to glucose substrate diffusion 
under normoglycemia are less limiting metabolically in regards to this substrate. At this point, 
since these regions of tumor tissue are no longer biochemically limited in their energy 
production from glucose, they might be able to better resist the effects of chemotherapy, as 
oppose to the more vulnerable state where glucose was limited. For these reasons, that is why 
we failed to see much lower pH levels in the tumors and also determined a decrease in efficacy 
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of response to melphalan under hyperglycemic conditions in these experiments. Furthermore, 
the improved energetics mitigated minimized any increase in DNA alkylation response 
resulting from with acute hyperglycemia. 
Mechanism of Action of Lonidamine (LND) at the Level of Mitochondrial Pyruvate 
Carrier  
Inhibition of lactate export also might not suffice to cause intracellular acidification since 
lactate is in equilibrium with pyruvate, which could be exported to the mitochondria where it 
could be converted to acetyl-CoA by pyruvate dehydrogenase and then be completely oxidized 
via the TCA cycle. If this occurred, inhibition of mitochondrial oxidation of pyruvate would be 
essential to cause tumor acidification. Thus, under hyperglycemic conditions with addition of a 
mitochondrial inhibitor such as meta-iodobenzyl guanidine (MIBG), a Complex I inhibitor, 
tumor acidification has been noted by Kuin et al. (41), Burd et al. (42) and by Zhou et al. (29). 
However, MIBG cannot be used in the clinic at the therapeutic doses required to produce 
tumor acidification. Similar effects might be produced by metformin that is Food and Drug 
Administration (FDA) approved Complex I inhibitors (43-49). However, Zhou et al. (30) also 
found that CHC produced selective acidification and de-energization of DB-1 melanomas, and 
Halestrap et al. (21, 31) had shown that this agent inhibits both MCT1 and MCT4 while also 
inhibiting the MPC, thus blocking oxidation of pyruvate. However, CHC inhibits lactate export 
and oxidation for relatively short periods of time and is not approved for clinical use, whereas 
LND has been used extensively in Europe and Canada and with special FDA permission in the 
US. This drug produces a much more robust and sustained effect on tumor pHi and NTP levels. 
Nath et al. (6, 7) proposed that LND also inhibited both the MPC and the MCT and Nancolas 
et al. (50) provided direct proof of this hypothesis. These authors demonstrated that LND 
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induced inhibition of MPC activity in isolated liver mitochondria and also inhibited the activity 
of MCT1, MCT2 and MCT4 expressed in Xenopus laevis oocytes. Of particular note they 
showed that the IC50 for MPC inhibition is about an order of magnitude lower than for 
inhibition of the MCTs. Thus, the MPC inhibition is likely to be playing a critical role in this 
process even though previous studies have attributed tumor acidification exclusively to 
inhibition of the MCTs (50) (Figure 3). 
Lonidamine (LND) Inhibits Uncoupled Mitochondrial Pyruvate Oxidation more Potently 
than Glutamate + Malate or Succinate Oxidation 
Nancolas et al (50) demonstrated that pyruvate oxidation by uncoupled mitochondria was 
inhibited by LND more potently than glutamate + malate or succinate oxidation. The effect of 
LND on uncoupled pyruvate oxidation by rat heart mitochondria was significantly greater than 
on the oxidation of other respiratory substrates, which is entirely consistent with a dominant 
effect of the inhibitor on the MPC as opposed to the respiratory chain (Figure 4). 
Liver mitochondria, unlike heart mitochondria, do not oxidize pyruvate rapidly, and the MPC 
does not exert much control over its oxidation (50). However, uncoupled respiration in the 
presence of either glutamate + malate or succinate (in the presence of rotenone) is rapid, and 
the data of figure 3 confirm that LND inhibits both with IC50 values of 25 and 150 μM, 
respectively. 
Mechanism of Action of Lonidamine (LND) at the Level of Monocarboxylate Transporter  
Full exploitation of LND’s role as a sensitizer in cancer therapy requires delineation of its 
detailed mechanism of action, which has been the subject of considerable controversy. The 
initial claim that LND inhibited glycolysis at the level of mitochondrial hexokinase II was 
based on decreases in extracellular lactic acid, which appear artifactual in light of strong 
14 
 
evidence that this drug was inhibiting lactate export from tumor cells (19, 22). However, the 
evidence for inhibition of the MCT, while convincing, was indirect with definitive 
identification of which isoform(s) of MCT were involved and their affinities for the drug yet to 
be identified. Because of the similarity of LND to CHC in its ability to selectively lower the 
pHi and NTP levels of melanoma, Nath et al. (7) suggested that LND also inhibits the 
mitochondrial pyruvate carrier (MPC). There was strong evidence for MCT inhibition by CHC 
(30) but none for LND until Nancolas et al. (50) recently published their findings. Finally, as 
noted above, there was also additional evidence to those presented by Floridi and Lehninger 
(25) that LND also inhibits respiration, but the site and detailed mechanism of inhibition 
remained to be determined. 
Inhibition of lactate export was based on indirect evidence of retention of lactate by 
tumor cells. However, the proposal that inhibition of the MCT was responsible for this 
decrease was purely hypothetical.  Nancolas et al. recently provided the first direct proof that 
this is, in fact, the case and identified specific MCT isoforms involved. Transport through 
MCT1, MCT2, and MCT4 are all inhibited cooperatively with similar K0.5 values (36-40 μM) 
and Hill Coefficients (1.65-1.85), but only MCT1 and MCT4 are detected in DB-1 melanomas 
at approximately equal levels (50). However, MCT1 and MCT4 have Km values for lactate of 
about 4.5 mM and 22 mM, respectively (51). Therefore, the dominant effect on inhibition of 
lactate export by LND can probably be attributed to inhibition of MCT1 (Figure 5). 
Mechanism of Action of Lonidamine (LND) at the Level of Complex II of Electron 
Transport Chain (ETC) 
Using the liquid chromatography-selected reaction monitoring/mass spectrometry (LC-
SRM/MS) technique, Guo et al (52) recently demonstrated that in DB-1 cells treated with 
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LND, the levels of succinate and α-ketoglutarate increased whereas levels of citrate, fumarate 
and malate decreased (Figure 6). The oxidation of succinate to fumarate is catalyzed by the 
succinate dehydrogenase activity of Complex II. Floridi and Lehninger (25) first recognized 
that LND inhibited mitochondrial respiration. They attributed this to inhibition of the electron-
transfer chain, but could not unambiguously identify the specific locus of inhibition. The 
cellular accumulation of succinate and inhibition of succinate dependent mitochondria 
respiration indicate Complex II is one of the sites of this activity (Figure 7). Complex II or 
succinate dehydrogenase (SDH) consists of four basic components delineated as SDHA, which 
oxidizes succinate to fumarate while reducing FAD to FADH2, SDHB which contains three 
iron-sulfur clusters, and SDHC and SDHD, contain a heme moiety and reduce ubiquinone (Q) 
to ubiquinone dihydride (QH2), respectively (Figure 7). With the aid of electron acceptor dyes 
that interact with specific components of Complex II (Figure 7), Guo et al. have demonstrated 
that SDHA and SDHB are not significantly inhibited by LND. Hence, the inhibitory effect of 
LND on SDH must be on the SDHC – SDHD moiety involving transfer of electrons from the 
iron sulfur clusters to ubiquinone. A more extensive description of the effects of LND on 
Complex II is presented by Guo et al. (52) 
Other Effects of Lonidamine (LND) 
Lonidamine (LND) Induces Reactive Oxygen Species (ROS) Formation and Cell Death 
It has been reported that Complex II is a source of ROS from either the reduced FAD or 
ubiquinone site when downstream components of the ETC are blocked (52-54). Guo et al. (52) 
have quantified the level of ROS by the dichlorodihydrofluorescein (DCF) fluorescence 
technique to examine whether LND induces intracellular ROS generation. The ROS generated 
upon LND treatment can be partially reduced by 3-nitropropionic acid (3-NPA) and further 
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enhanced by thenoyltrifluoroacetone (TTFA), indicating that LND induces ROS at a site within 
Complex II downstream of SDHA. Guo et al. (52) have also shown that LND induces 
substantial cell death after treatment of DB-1 cells for 24 h or 48 h.   
Lonidamine (LND) Reduces Cellular Levels of Glutathione and NADPH and the Pentose 
Phosphate Pathway (PPP)  
Guo et al. (52) compared the cellular levels of GSH and antioxidants in LND and TTFA-
treated DB-1 tumor cells. LND caused a 40% drop in GSH levels at a concentration of 150 µM 
and above. In contrast, TTFA (50 or 200 µM) caused a modest reduction of 6%, indicating that 
this effect is independent of Complex II inhibition. Consistent with the reduced GSH levels, 
the levels of NADPH as well as the NADPH/NADP
+
 ratio were both decreased after LND-
treatment but not after TTFA-treatment. The pentose phosphate pathway (PPP) is an important 
source of NADPH (55) required for the GSH-reductase mediated reduction of glutathione 
disulfide (GSSG) to GSH (56).  
Role of Lonidamine (LND) as Inhibitor of Hexokinase  
LND has been reported to be an inhibitor of hexokinase (17-20), which catalyzes the first step 
of glycolysis. Therefore, it is possible that both the PPP and glycolysis are inhibited in DB-1 
cells. In support of this hypothesis, the cellular concentration of 6-phosphogluconate (6-PG), 
an important PPP metabolite, was markedly decreased in LND treated cells (52). In addition, a 
time-course for the incorporation of [
13
C6]-glucose into PPP metabolites (determined by Liquid 
chromatography–mass spectrometry (LC-MS)) revealed that incorporation into the M+6 
isotopologue, [
13
C6]-6-PG as well as the glycolytic metabolite [
13
C6]-fructose-1,6-bisphosphate 
(Fru-1,6-BP) were significantly delayed. These data, together with the reduced levels of 6-PG, 
suggest that flux into the PPP was greatly reduced by LND, possibly through inhibition of 
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hexokinase. Thus, the reduced NADPH and glutathione (GSH) levels in LND treated cells 
resulted, in part, from inhibition of the PPP (52). 
Ben-Horin et al. (26) co-administered 2-deoxyglucose (2DG), a well-documented inhibitor of 
hexokinase, and used the 2DG resonance to evaluate possible competitive inhibition by LND 
for which no evidence was found. However, failure to find such indirect evidence for 
hexokinase inhibition does not definitively rule it out. The authors also concluded that the 
apparent inhibition of glycolysis by LND was really an artifact caused by using extracellular 
lactate as the indicator of glycolytic activity. They concluded that inhibition of the MCT rather 
than inhibition of hexokinase was the cause of the drop in extracellular lactate produced by 
LND. 
Ben-Yoseph et al. (28) claimed that the lack of effects of LND on either soluble or particulate 
(i.e., mitochondrial-bound) hexokinase or on relative flux through the PPP of cultured 9L cells 
(monitored by GC-MS analysis of [1,6-
13
C2, 6,6-
2
H] glucose) confirmed that LND was not 
inhibiting mitochondrial hexokinase. This argument appears inconclusive since hexokinase 
produces glucose-6-phosphate that could enter either the pentose shunt or the glycolytic 
pathway and need not affect the relative flux through the two pathways, so direct evidence of 
the absence of hexokinase inhibition by LND appears to have been missing. 
In summary, Floridi reported that LND inhibited hexokinase II (19, 20). Ben-Horin et al. (26) 
found no evidence of any effect of LND on the hexokinase-2DG complex, suggesting that 
LND may not interact with hexokinase II but not directly proving that this inhibition did not 
occur.  Ben-Yoseph et al. (28) found that LND did not change relative flux through the PPP vs. 
glycolysis and suggested that this contradicted the claim of Floridi et al. (19, 20), but relative 
flux through the PPP and glycolysis would not be changed if hexokinase II were inhibited since 
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hexokinase acts upstream of glucose-6-phosphate and would affect both of these pathways 
equivalently. The data of Guo et al. (52) suggest substantial decreases in flux through the PPP 
and glycolytic pathways, which may be consistent with inhibition of hexokinase II but does not 
prove it since inhibition of these pathways could result from other mechanisms such as acid 
inhibition of specific enzymes in the PPP and glycolytic pathways. Sadaeghi et al. (18) have 
reported the inhibition of hexokinase with 600 µM LND in prostate cancer cells using glucose 
6-phosphate dehydrogenase (G6PD)-coupled assay. Cervantes-Madrid et al. (17) have also 
suggested the inhibitory effects of LND on hexokinase based on genetic manipulation of 
hexokinase mRNA. 
Role of
 13
C Metabolic Modeling to Study the Effects of Lonidamine (LND)  
To understand the regulation of the cancer metabolic network and to mechanistically evaluate 
the mechanism of action of LND, quantitative models should be used to interrogate altered 
metabolic pathways. To quantitatively model the metabolic pathways related to energy and 
other intermediary metabolism, we use 
13
C metabolic modeling techniques called Bonded 
Cumomer and Fragmented Cumomer Analysis for analysis of 
13
C MRS and LC-MS data, 
respectively. These techniques provide a detailed picture of metabolism at the level of in vivo 
enzyme activities, whole pathways and on the integrated systems level. A three-compartment 
metabolic model which included extracellular medium, cell cytoplasm and the mitochondria, 
was used to fit 
13
C steady state or time courses of labeled metabolites to determine the 
metabolic and inter-compartmental transport fluxes. The main intermediary metabolic 
pathways including glycolysis, TCA cycle, PPP, a-ketoglutarate-glutamate and oxaloacetate-
aspartate exchange (to model malate-aspartate shuttle), pyruvate carboxylase activity, 
anaplerosis at the succinyl-CoA level, pyruvate recycling through malic enzyme, 
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glutaminolysis, reductive carboxylation and lactate dehydrogenase activity were included in 
the melanoma bionetwork. To express the model mathematically, we have used: 1) mass 
balances for the total metabolite concentration in medium, cytosol, mitochondria, and 2) 
13
C 
isotopomer mass balance for labeled metabolites. Transport of the main nutrients utilized by 
cancer cells were included in the model: the perfused labeled glucose, lactate and glutamine 
transported from the extracellular medium to the cancer cells and vice versa assuming 
reversible non-steady-state Michaelis-Menten transport kinetics through corresponding 
transporters. Isotopomer balance equations were derived for all bonded cumomers of orders 1, 
2, and 3 of participating metabolites (32, 57, 58). Fine structure multiplets were completely 
described by each metabolite’s bonded cumomers (32, 57, 58) of order 1, 2, and 3 using 
connection matrices between bonded cumomers and 
13
C fine multiplets (32, 57, 58). The use of 
bonded and fragmented cumomer techniques leads to a reduced number of equations compared 
to a model including all possible isotopomers while retaining all the NMR- and MS-
measurable isotopomer information. The errors for the obtained fluxes and other metabolic 
parameters were estimated using Monte Carlo simulations with experimental noise levels (59).  
By using these modeling techniques we were able to determine activities of various key 
metabolic pathways, e.g., glutaminolysis and reductive carboxylation in cancer for the first 
time to the best of our knowledge, which we have discussed in the next section. 
Lonidamine (LND) Increases the Contribution of Glutamine to the TCA Cycle through 
Oxidative Metabolism and Reduces Glutamine-Dependent Reductive Carboxylation 
Many cancer cells depend on glutamine to sustain bioenergetics, building blocks and redox 
balance. To determine whether LND altered flux from glutamine into TCA cycle and 
production of citrate through reductive carboxylation, Guo et al. (52) used [U-
13
C5, U-
15
N2] 
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glutamine tracing combined with a three-compartment metabolic flux modeling discussed 
above to demonstrate that glutaminolysis pathway as mentioned in above section was 
significantly higher in LND treated cells (increase from 0.9 mM/h to 2.1 mM/h with LND 
treated cells). The enhanced glutamine utilization in LND treated cells was underscored by 
their increased glutamine uptake during 12 h incubation.  Guo et al. (52) also showed that DB-
1 cells metabolize glutamine through reductive carboxylation as demonstrated by the formation 
of malate and fumarate M+3 isotopologues and the citrate M+5 isotopologue. LND lowered 
the reductive carboxylation pathway by nearly 50%, from 2.2 mM/h in control to 1.2 mM/h 
with LND treatment. In contrast, the reductive carboxylation flux was unchanged in TTFA-
treated cells, indicating this effect is independent of Complex II inhibition.  
13
C NMR Experiments to Study Effects of Lonidamine (LND) 
We have performed a 
13
C NMR study of DB-1 melanoma cells cultured in flasks. The cells 
confluent on the T-150 flasks were treated with either vehicle or 150 µM LND for 6 hr in 
DMEM with glucose substituted by 8 mM [1,6-
13
C2] glucose. 1.5×10
7
 cells from each flask 
were harvested using 0.05% trypsin-EDTA (Gibco, Thermo Fisher Scientific Inc., 
Philadelphia, PA). Water-soluble metabolites were extracted using a perchloric acid extraction 
procedure (60). The dried metabolites were dissolved in 300 µl of D2O, containing 0.05% 
(w/v) trimethylsilyl propionic acid (Sigma Aldrich, St. Louis, MO) as an internal reference, 
and inserted into a 5 mm Shigemi NMR tube (Wilmad-Lab Glass, Inc, Vineland, NJ). 
13
C 
NMR experiments were run (~15 hr) in a 400 MHz NMR spectrometer (Agilent Technologies 
Inc., Wilmington, DE) with proton decoupling and nuclear Overhauser enhancement. Figure 8 
shows the 
13
C NMR spectra of vehicle- and LND-treated DB-1 cells. The intracellular C3-
lactate increased 4-fold after LND treatment. The result is consistent with LND blocking 
lactate export by inhibiting the monocarboxylate transporters (50). The TCA cycle metabolite 
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C4- and C3-glutamate did not change significantly after treatment with LND. However, the 
alanine level increased 2-fold after treatment. Alanine can enter mitochondria independently of 
the MPC and thus provide a source of pyruvate to maintain TCA cycle intermediates (61). An 
analysis is in progress to quantitatively evaluate detailed metabolic fluxes (32) in response to 
LND under these conditions. 
 Effects of Lonidamine (LND) on L-lactate Output by DB-1 Melanoma cells 
Nancolas et al. detected (50) inhibition of MPC at low concentrations of LND resulting in a 
decrease in pyruvate oxidation and an increase in L-lactate. Higher LND concentrations were 
required for inhibition of the MCTs, decreasing L-lactic acid cellular efflux with a 
corresponding rise in levels of intracellular [L-lactate]. They found that 1-10 μM LND 
increased L-lactate output, consistent with MPC inhibition, and this occurred without a 
detectable increase in intracellular lactate concentration. However, higher LND concentrations, 
40 μM and 150 μM, caused intracellular [L-lactate] to increase by two-fold and eight-fold, 
respectively, with a corresponding decrease in L-lactate output, consistent with MCT inhibition 
as a result of intracellular acidification that inhibited glycolytic enzyme activity (52). 
Lonidamine (LND) Toxicity 
Price et al. (15, 16) reported that dogs administered single doses of 400 mg/m
2
 LND 
intravenously and 1200 mg/m
2
 orally twice daily exhibited signs of acute hepatic and 
pancreatic toxicity with one quarter of these animals showing increases in alanine amino 
transferase (ALT) activity. However, no toxicity was noted at half this oral dose. Also, a 
clinical trial of LND chronically administered orally to humans for treatment of benign prostate 
hyperplasia was terminated when six out of more than eight hundred patients exhibited 
elevations in liver ALT and AST enzymes. Thus, reports of liver toxicity after prolonged 
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treatment with LND at elevated levels can probably be attributed to accumulation of the drug 
in the liver, but this might be avoided by single intravenous administration of doses of 400 
mg/m
2
 or less. There have also been reports of myalgia (16% in a breast cancer study (62-64) 
and testicular pain (65-67) which again may be due to higher levels of LND reaching the 
plasma following oral administration. Myalgia can be avoided by bed rest; the absence of 
effects on skeletal muscle in mouse studies may be attributed to the animals being sedated 
throughout the experiments. We suspect that the transient effects on liver pHi and NTP/Pi 
resulted from transient accumulation of LND in the liver that was quickly washed out or 
detoxified. LND pharmacokinetic studies have been investigated in advanced breast cancer 
(68) and lung cancer patients (69) as part of phase II evaluation of the LND with wide variation 
in plasma concentration. Detailed Phase II clinical trials of LND have been performed in 
patients with breast cancer (70-73), lung cancer (74-76), ovarian cancer (77-80), and head neck 
cancer (81-83). Phase III clinical trials have also been performed on metastatic breast cancer 
(84-88) and lung cancer (89-93) patients. Overall, treatment with LND appears to be free of 
significant toxicity to normal tissues and such toxicity that is encountered can be ameliorated 
or avoided by intravenous administration of proper doses (6, 7). Tumor selectivity and low 
toxicity to normal tissues are critical characteristics that make LND an attractive agent for 
treatment of cancer by potentiating the activity of other agents (6, 7). 
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Conclusions and Perspectives 
The most avid site for LND activity appears to be the MPC with an IC50 of 2.5 M. The sites 
with the next highest affinity for LND are the MCTs with MCT1, MCT2 and MCT4 all 
exhibiting K0.5 values of 36-40 M. Simultaneous inhibition of the MPC and MCT1 as well as 
MCT4 is essential for intracellular tumor acidification, but inhibition of the MPC may suffice 
to produce tumor de-energization. Further contributions to tumor de-energization appear to 
result from inhibition of the ETC (Electron Transport Chain) at Complex II and perhaps also 
Complex I, since both sites involve ubiquinone reduction, but these effects occur at higher 
LND concentrations. Other effects on hexokinase, other glycolytic and PPP enzymes are 
probably secondary to tumor acidification.   
Selective effects of LND on tumors compared to other potential targets probably result 
from dependence of most tumors on glycolytic metabolism, but the exact mechanism of 
specificity is still not fully known. 
The primary clinical utility of LND derives from its selective effect on tumors, 
producing intracellular acidosis and depletion of NTP pools. This potentiates the response of 
tumors to a variety of cancer drugs such as N-mustards, anthracyclines, and also enhances the 
effect of hyperthermia, radiation therapy and photodynamic therapy. A variety of mechanism 
may be responsible for these potentiation effects including cation trapping of weak bases, 
stabilization of active intermediates like aziridinium ions by acid, inhibition of glutathione-
transferase and 
6
O-alkyltransferase and perhaps other DNA repair enzymes by acid as well 
diminution of multidrug resistance pumps by decreases in tumor energy levels. 
Key problems that remain to be addressed are production of LND under GMP 
conditions since Angelini Pharmaceuticals in Rome, Italy, the sole commercial source of this 
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drug, stopped producing it in 2006. In addition, utilization of LND in the US requires IND 
approval by the FDA, which has previously been granted for a number of clinical trials (68, 94, 
95). Finally, even though LND is a potent enhancer of the activity of a number of potent anti-
cancer agents, potentially less toxic (and patentable) “targeted-tumor agents” are replacing 
traditional chemotherapy. Another problem remaining to be addressed is the limited solubility 
of LND at neutral pH. Oral delivery has led to variable results; more soluble derivatives that 
can be administered by intravenous administration are needed to accurately control the dosing 
schedules. More study may be required to determine why LND is so selective for tumor cells 
even though it inhibits isolated uncoupled liver and heart mitochondria. 
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Table 1. Summary of ∆pHi, ∆pHe and ∆βNTP/Pi of human tumor xenografts measured by 31P 
magnetic resonance spectroscopy (
31
P-MRS) following lonidamine (LND) treatment. 
Parameter 
DB-1 
melanoma 
Xenografts 
(n = 15) 
BT-474 
breast cancer 
xenografts 
(n = 3) 
HCC1806 
breast cancer 
xenografts 
(n = 3) 
A2780 
ovarian cancer 
xenografts 
(n = 3) 
LNCaP 
prostate cancer 
xenografts 
(n = 3) 
∆pHi 0.60 ± 0.1 
P < 0.05 
0.44 ± 0.14 
P = 0.05 
0.54 ± 0.23 
P < 0.05 
0.56 ± 0.10 
P < 0.05 
0.47 ± 0.11 
P < 0.05 
 
∆pHe 
 
0.20 ± 0.07 
P < 0.05 
 
0.22 ± 0.07 
P = 0.05 
 
0.28 ± 0.19 
P = 0.05 
 
0.34 ± 0.23 
P = 0.05 
 
0.30 ± 0.13 
P > 0.05 
 
∆βNTP/Pi 
 
 
66.8 ± 5.7% 
P < 0.05 
 
70.0 ± 0.12% 
P < 0.05 
 
77.0 ± 0.09% 
P < 0.05 
 
70.0 ± 0.22% 
P < 0.05 
 
77.5 ± 0.04% 
P < 0.05 
 
Note: The pH values and bioenergetics (∆βNTP/Pi) were determined by 31P-MRS. Data are 
presented as mean ± S.E.M. This research was originally published in NMR Biomed (7, 8).   
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Table 2. Summary of estimated growth delay (T-C), doubling time (Td) and surviving fraction 
as a percentage {100×exp[−(T−C)×B], with bootstrap 95% confidence interval (CI)}, via the 
log cell kill method, by experiment and treatment arm in DB-1 human melanoma and HCC 
1806 breast cancer xenografts. 
 Experiment 
Treatment 
 
DB-1 Melanoma 
xenografts 
treated with 
Melphalan 
(7.5 mg/kg; i.v.) 
 
DB-1 Melanoma 
xenografts treated with 
Doxorubicin 
(7.5 mg/kg; i.v.) 
 
DB-1 Melanoma 
xenografts treated with 
Doxorubicin 
(10 mg/kg; i.v.) 
HCC1806 Breast cancer 
xenografts 
treated  with 
Doxorubicin 
(12 mg/kg; i.v.) 
 
 
T-C 
(days) 
Td 
(days) 
Surviving 
fraction 
(%) 
T-C 
(days) 
Td 
(days) 
Surviving 
fraction 
(%) 
T-C 
(days) 
Td 
(days) 
Surviving 
fraction 
(%) 
T-C 
(days) 
Td 
(days) 
Surviving 
fraction 
(%) 
             
Lonidamine 
(100 mg/kg; 
i.p.) 
1.99 6.50 
81 
(46, 158) 
4.89 4.79 
49 
(27, 82) 
2.34 5.01 
72 
(45, 121) 
2.31 3.16 
60 
(20, 204) 
Melphalan 7.62 5.91 
 
41 
(13, 108) 
- - - - - - - - - 
 
Doxorubicin - - - 4.58 4.19 
 
47 
(23, 83) 
5.43 5.04 
47 
(28, 81) 
6.70 3.16 
23 
(11, 52) 
 
Lonidamine 
+ 
Melphalan 
 
17.75 
 
5.32 
 
10 
(4, 28) 
- - - - - - - - - 
Lonidamine 
+ 
Doxorubicin 
- - - 18.2 4.26 
5  
(2, 14) 
28.57 5.20 
2  
(1, 10) 
13.39 3.16 
5  
(3, 10) 
 
Note:  T, average slope across both arms of the study; C, median time (in days) required for the 
treatment group tumors to reach a predetermined size. This research was originally published 
in NMR Biomed (7, 8). 
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Figure Legends 
 
Figure 1. The intracellular pH (pHi), extracellular pH (pHe), bioenergetics and lactate profile
 
of human melanoma xenograft after lonidamine (LND) administration.  
A) In vivo localized (Image Selected In vivo Spectroscopy-ISIS) 31-Phosphorus magnetic 
resonance spectroscopy (
31
P MRS) spectra of a human melanoma xenograft grown 
subcutaneously in nude mice (lower) pre- and (upper) 180 min post administration of LND 
(100 mg/kg, i.p.). Resonance assignments are as follows, 3-APP (3-aminopropylphosphonate); 
PME (phosphomonoesters); Pi (inorganic phosphate); PDE (phosphodiesters); γNTP (γ 
nucleoside-triphosphate), αNTP (α nucleoside-triphosphate), βNTP (β nucleoside-
triphosphate). Decrease in βNTP levels and the corresponding increase in Pi following LND 
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administration (Upper spectrum of panel A) indicating impaired energy metabolism. B) pHi, 
pHe profile as a function of time. C) The changes of bioenergetics (βNTP/Pi) (ratio of peak 
area) relative to baseline D) Change in tumor lactate as a function of time, inset picture 
showing lactate spectra using 
1
H MRS with Hadamard Selective Multiquantum coherence 
transfer pulse sequence in human melanoma xenografts. Area under the curve was compared to 
baseline at each time point and was normalized to baseline levels as a function of time in 
response to LND (100 mg/kg; i.p.) administered at time zero. The values are presented as mean 
± S.E.M. When not displayed, S.E.M. values were smaller than the symbol size. Part of this 
research was originally published in NMR Biomed (7) and modified in the current review 
manuscript. 
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Figure 2. Representative growth delay experiments performed on DB-1 human melanoma 
xenografts in nude mice. 
Animals were treated on Day 0 as follows: Control (sham i.p. tris/glycine buffer + sham i.v. 
PBS), LND (100 mg/kg i.p.), melphalan (7.5 mg/kg i.v.), lonidamine (LND) + melphalan. 
Mice were treated on day 0 as follows: Control (sham intraperitoneal Tris/glycine buffer + 
sham intravenous phosphate-buffered saline (PBS)), lonidamine (LND), melphalan, LND + 
melphalan. This allows each tumor to serve as its own control. As such, day 0 is equal to 100% 
for each tumor. In LND + melphalan cohorts melphalan was injected 40 min. later after the 
injection of LND in order to get optimal intracellular acidification. The values shown are 
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means ± standard error of the mean (SEM) of n = 4 animals in the control and LND groups, n 
= 3 animals in the melphalan and LND + melphalan groups. When not shown, error bars are 
smaller than the symbol size. The data yielded tumor growth delays in a representative 
experiment of 1.1 ± 0.1, 6.6 ± 0.0 and 19.9 ± 2.0 days for LND alone, melphalan   alone and 
LND + melphalan, respectively. This research was originally published in NMR Biomed (7). 
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Figure 3. Lonidamine (LND) inhibits pyruvate transport into mitochondria.  
In Panel A) pyruvate transport into liver mitochondria was assayed directly at 9oC using [1-
14C]-pyruvate as described under methods section of Nancolas et al (50). Data are presented as 
Means ± S.E.M. for 3 separate mitochondrial preparations. In each experiment, four replicates 
were performed at each LND concentration and the average value taken to calculate the extent 
of inhibition as percentage of control (no LND). Data were fitted to the standard inhibition 
equation (methods section of Nancolas et al (50)) to give a derived inhibitory constant (Ki) 
value of 2.5 ± 0.1 µM. The absolute rate of pyruvate (60 µM uptake in the absence of LND 
was 0.303 ± 0.032 nmol/mg protein in 45s. Panel B) shows data for the inhibition of uncoupled 
pyruvate oxidation by isolated rat heart mitochondria at 30oC measured using an oxygen 
electrode as described under methods section of Nancolas et al (50). Mean data (± S.E.M.) are 
presented for 3 separate mitochondrial preparations. The absolute rate of pyruvate oxidation in 
the absence of LND was 87.9 ± 5.8 nmol O2 per mg protein per min. The data were fitted to an 
equation that assumes oxidation of pyruvate is set by the activity pyruvate dehydrogenase 
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(PDH) which in turn is controlled by the rate of pyruvate transport relative to that of PDH as 
described under methods section of Nancolas et al (50). The Ki value for LND of 2.5 µM 
derived from Panel A was employed and the Vmax of PDH and MPC activity (expressed as % 
control rate of oxygen consumption and ± S.E.) were then calculated by least squares 
regression analysis to be 127 ± 6.3 and 233 ± 9.1, respectively. This research was originally 
published in Biochem J (50).  
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Figure 4. Lonidamine (LND) inhibits oxidation of glutamate, 2-oxoglutarate and succinate by 
uncoupled rat heart and liver mitochondria less potently than pyruvate transport. 
Rates of oxidation by isolated rat liver A) or heart B) mitochondria at 30oC were measured 
using an oxygen electrode as described under methods section of Nancolas et al. (50). Data are 
expressed as the percentage of rates in the absence of LND to allow better comparison between 
the different substrates and the lines drawn were fitted by FigSys using a Bezier Spline 
function. For heart mitochondria, data are presented for a single representative experiment with 
absolute rates of pyruvate + malate, glutamate + malate, 2-oxoglutarate + malate and succinate 
+ rotenone oxidation in the absence of LND of 84, 83, 67 and 212 nmol O2 per mg protein per 
min, respectively. For liver mitochondria A), mean data (± S.E.M.) are presented for 3 separate 
mitochondrial preparations. The absolute rates of glutamate + malate and succinate (+ 
rotenone) oxidation in the absence of LND were 67.9 ± 3.0 and 109 ± 7.8 nmol O2 per mg 
protein per min, respectively. This research was originally published in Biochem J (50). 
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Figure 5. Lonidamine (LND) inhibits the proton-linked monocarboxylate carriers MCT1, 
MCT2 and MCT4. 
[U-14C]-L-lactate uptake into Xenopus laevis oocytes expressing the MCT isoform indicated 
was determined as described in Methods. Panel A) shows the absolute rates of L-lactate uptake 
while Panels B-D) show the effects of increasing concentrations of LND on rates of L-lactate 
uptake into oocytes expressing MCT1, MCT2 or MCT4 as indicated. Rates are expressed as a 
percentage of the control (no LND) after subtraction of the uptake by water-injected oocytes. 
Each data point represents mean data ± S.E.M. for 10-45 individual oocytes and data were 
fitted to the equation for cooperative inhibition using FigSys as described in methods of 
Nancolas et al (50). The derived values for K0.5 and the Hill Coefficient (n) are indicated on 
each plot (± S.E. of the fit shown). This research was originally published in Biochem J (50).  
C 
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Figure 6. Lonidamine (LND) alters TCA cycle intermediates. 
LND treatment (150 µM) in DB-1 melanoma cells increases the intracellular levels of lactate, 
α-ketoglutarate and succinate with concurrent reduction in the levels of citrate, fumarate and 
malate. Part of this research was originally published in J Biol Chem (52) and modified in the 
current review manuscript. 
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Figure 7. Lonidamine (LND) inhibits the SQR activity of Complex II. 
A schematic representation of Complex II subunits and enzyme activities. Complex II contains 
four subunits: succinate dehydrogenase A (SDHA; flavoprotein), succinate dehydrogenase B 
(SDHB; iron-sulfur subunit), succinate dehydrogenase C (SDHC; integral membrane protein) 
and succinate dehydrogenase D (SDHD; cytochrome b small subunit). Flavin adenine 
dinucleotide (FAD) cofactor bound to SDHA obtains electrons from succinate oxidation. The 
electrons are then passed to the Fe-S clusters of SDHB and finally to the ubiquinone reduction 
site within SDHC and SDHD where ubiquinone (Q) is reduced to ubiquinol (QH2). LND 
inhibits the succinate ubiquinone reductase (SQP) activity of Complex II, whereas it has 
minimal effect on the SDH of Complex II. SQP activity was measured by electron transfer 
from succinate to decylubiquinone and 2,6-dichlorophenolindophenol (DCPIP). SDH of 
Complex II was determined by the electron transfer from succinate to iron-sulfur cluster and 
finally to phenazine methosulfate (PMS) and 2-(4,5-dimethyl-2-thiazolyl)-3,5-diphenyl-2H-
tetrazolium bromide (MTT). Part of this research was originally published in J Biol Chem (52). 
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Figure 8. 
13
C NMR of DB-1 melanoma cells with lonidamine (LND) treatment.  
13
C NMR spectra of DB-1 melanoma cells after 6 hr incubation in 8 mM [1,6-
13
C2] glucose 
containing medium without A) and with B) LND. Resonance assignments are as follows: C4-
Glu (C4-glutamate), C3-Glu (C3-glutamate), C3-Lac (C3-lactate), C3-Ala (C3-alanine), TSP 
(trimethylsilyl propionic acid).  
 
